Association of NLR at baseline, at 6-weeks, and change at week 6 (±2 weeks) with treatment outcomes in multivariable Cox and Logistic regression models
| ORR (CR + PR) | PFS | OS | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Total N/ N response | Adjusted-ORb | p-value | Total N/ N event | Adjusted-HRb | p-value | Total N/ N event | Adjusted-HRb | p-value | |
| Continuous Ln(NLR) [baseline] | 142/44 | 0.49 (0.22–1.09) | 0.081 | 142/96 | 1.80 (1.14–2.86) | 0.012 | 142/51 | 1.70 (0.99–2.94) | 0.056 |
| Continuous Ln(NLR) [6-weeks]a | 134/44 | 0.22 (0.10–0.52) | 0.001 | 117/72 | 3.61 (2.21–5.88) | <0.001 | 134/46 | 2.51 (1.71–3.69) | <0.001 |
| NLR-change [6-weeks]a | |||||||||
| Decrease ≥25% | 28/12 | 1.52 (0.49–4.68) | 0.112 | 27/13 | 0.55 (0.26–1.18) | <0.001 | 28/6 | 0.33 (0.12–0.88) | 0.004 |
| No change | 58/21 | 1.00 (reference) | 53/30 | 1.00 (reference) | 58/18 | 1.00 (reference) | |||
| Increase ≥25% | 48/11 | 0.45 (0.18–1.16) | 37/29 | 2.60 (1.53–4.39) | 48/22 | 1.57 (0.83–2.99) | |||
Abbreviations: ORR objective response rate, CR complete response, PR partial response, OR odds ratio, PFS progression free survival, HR hazard ratio, OS overall survival
aLandmark approach was used where OS and PFS were calculated from 6 weeks after therapy initiation. Patients who progressed before the 6 week landmark time were excluded for PFS analysis
bAdjusted for line of therapy, number of IMDC risk factors, histology (clear cell RCC vs non-clear cell RCC); baseline Ln(NLR) was also included as a covariate for the analysis of NLR change at 6 weeks. Boldface numerical values indicate statistically significant results